Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A consumer lawsuit says eyedrops are too big and wasteful. Photo: Will Russell/Getty Images

The Supreme Court on Monday declined to hear a case in which consumers argued drug companies such as Allergan and Alcon Laboratories purposefully make eyedrops too big, which the lawsuit says results in waste and "consumers purchasing more medication than they require." The pharmaceutical industry wanted the high court to intervene but now must face the lawsuit in lower court.

Go deeper: ProPublica profiled the issue of excessive eye drops last year.

Go deeper

Ina Fried, author of Login
13 mins ago - Technology

Tech's race problem is all about power

Illustration: Eniola Odetunde/Axios

As problematic as the tech industry's diversity statistics are, activists say the focus on those numbers overlooks a more fundamental problem — one less about numbers than about power.

What they're saying: In tech, they argue, decision-making power remains largely concentrated in the hands of white men. The result is an industry whose products and working conditions belie the industry rhetoric about changing the world for the better.

Mayors fear long-lasting effects of COVID-19

Data: Menino Survey of Mayors; Chart: Axios Visuals

U.S. mayors tend to be an optimistic bunch, but a poll released Thursday finds them unusually pessimistic about prospects for post-pandemic recovery.

Why it matters: In a survey of mayors of 130 U.S. cities with more than 75,000 residents, 80% expect racial health disparities to widen, and an alarming number predict that schools, transit systems and small businesses will continue to suffer through 2021 and beyond.

Coronavirus hospitalizations top 100,000 for the first time

Expand chart
Data: The COVID Tracking ProjectHarvard Global Health Institute; Cartogram: Danielle Alberti and Andrew Witherspoon/Axios

More than 100,000 Americans are now in the hospital with coronavirus infections — a new record, an indication that the pandemic is continuing to get worse and a reminder that the virus is still very dangerous.

Why it matters: Hospitalizations are a way to measure severe illnesses — and severe illnesses are on the rise across the U.S. In some areas, health systems and health care workers are already overwhelmed, and outbreaks are only getting worse.